B-Temia Inc. Obtains 510(k) Clearance for Keeogo™ from the USA Food & Drug Administration (FDA)

USA - English

• Deutschland - Deutsch

B-Temia Inc. gains commercial access to the United States of America

QUÉBEC CITY, Sept. 14, 2020 /PRNewswire/ - B-Temia Inc. (the "Company") announces that it received 510(k) clearance from the US regulator for the commercialization of its powered human mobility device Keeogo^TM Dermoskeleton System in the United States of America. This clearance opens the largest medical device market in the world.

Stéphane Bédard, Chief Executive Officer of B-Temia, says "The work we have accomplished since 2019 paved the way to this achievement. This is a major milestone for B-Temia. I am tremendously proud of our team since they were able to manage many challenges during the process to ensure that we reach our corporate objective. Keeogo^TM is a true disruptive product, with no comparable around the world, which made the alignment with the FDA challenging. This US market clearance is the biggest milestone of our global regulatory expansion, as the USA is the largest medical device market. It also gives us great confidence for the other regulatory approvals we are currently completing for additional territories". Mr. Bédard adds "B-Temia was created to allow people to regain their autonomy in mobility. This US clearance for stroke patients is a perfect example of the achievement of our mission."

Alexandre Jokic, Vice President Regulatory and Clinical Affairs, mentions, "We are pleased to confirm that the US FDA recognized our clinical trial strategy that demonstrates the clinical benefits and the immediate effect on gait quality for stroke patients and agreed on the demonstration of the safety and effectiveness of the Keeogo^TM Dermoskeleton^TM system. Keeogo^TM has been cleared for stroke patients having gait deficits and is intended to provide mobility assistance to the user in rehabilitation settings under the supervision of a trained healthcare professional for this population". Mr. Jokic adds, "We were appreciative of the work accomplished by all collaborators from all over the world, who we would like to thank, and the work done with the US regulator that allowed us to provide them all the necessary information to avoid any delay during the review process."

About Keeogo™
Keeogo^TM, short for "Keep on going", is a lower limb powered human mobility device developed by B-Temia. Its proprietary Dermoskeleton^TM technology is a novel type of lightweight exoskeleton that provides a true human- machine interface. It detects, responds and then supports an individual's movements with advanced software and motorized assistance. Keeogo^TM is a robotic exoskeleton intended to provide mobility assistance to the user based on their individual needs. It provides complementary knee strength and movement cues to assist trained healthcare professionals in rehabilitation and training of walking gait, sit-to-stand and stand-to-sit, squatting and stair climbing (ascent and descent). Keeogo^TM is intended for use in rehabilitation settings under supervision of a trained healthcare professional for use with stroke patients who fit the user assessment criteria. Keeogo^TM is not intended for sports. For more information, visit our web site www.keeogo.com.

About B-Temia Inc.
Founded in 2010, B-Temia is an innovative Canadian robotics tech company that develops and markets cutting-edge products for the growing market of human augmentation systems. B-Temia operates through a global network of companies, including B-Temia Inc., B-Temia Asia and B-Temia USA Inc., in the medical, industrial and military fields. B-Temia owns a patented technology called Dermoskeleton™ that restores, maintains or enhances the mobility of users. For more information, visit: www.b-temia.com.

SOURCE B-TEMIA

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED